HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab

Although current breast cancer treatment guidelines limit the use of HER2 blocking agents to tumors with HER2 gene amplification, recent retrospective analyses suggest that a wider group of patients may benefit from this therapy. Utilizing breast cancer cell lines, mouse xenograft models and matched...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ithimakin, Suthinee, Day, Kathleen C., Malik, Fayaz, Zen, Qin, Dawsey, Scott J., Bersano-Begey, Tom F., Quraishi, Ahmed A., Ignatoski, Kathleen Woods, Daignault, Stephanie, Davis, April, Hall, Christopher L., Palanisamy, Nallasivam, Heath, Amber N., Tawakkol, Nader, Luther, Tahra K., Clouthier, Shawn G., Chadwick, Whitney A., Day, Mark L., Kleer, Celina G., Thomas, Dafydd G., Hayes, Daniel F., Korkaya, Hasan, Wicha, Max S.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3600586/
https://ncbi.nlm.nih.gov/pubmed/23442322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-3349
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars